ImmunoVec
Santa Monica
About ImmunoVec
ImmunoVec develops gene therapy treatments to cure terminal genetic diseases of the immune system. Its gene therapy is intended for hematopoietic diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $45.0M
- Funding stage: Seed
- Last round: Grant (Sep 2025)
- Website: immunovec.com
Industries & Categories
Biotechnology, Genetics, Health Care, Medical
Canonical: https://fsome.com/organization/immunovec-19660 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.